KUALA LUMPUR: RHB Research has initiated coverage on Hovid with a Buy call and a fair value of 46 sen as it offered investors exposure to both the pharmaceutical and healthcare industries, with non-cyclical earnings and a global market reach.
It said on Monday Hovid's future revenue drivers include the "patent cliff' phenomenon, in-house drug development, and capacity expansion".
